- ROUNDTABLE: Pharmacy’s future in sync with technology
- FDA approves Upsher-Smith's Qudexy XR extended-release capsules
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
- DEA pushes forward on rescheduling hydrocodone combination products
- Harvard Heart Letter: Many consumers who supplement with aspirin don't need to
HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug for treating epilepsy, the company said.
The Indian generic drug maker announced the launch of lamotrigine extended-release tablets in the 25-mg, 50-mg, 100-mg, 200-mg and 300-mg strengths. The drug is being distributed in bottle sizes of 30.
Lamotrigine extended-release tablets are a generic version of GlaxoSmithKline's Lamictal XR, branded and generic versions of which had sales of $300.5 million during the 12-month period that ended in April, according to IMS Health.